Ionis reports third quarter 2025 financial results and highlights progress on key programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rebounds after Fed's first rate hike in years as oil, Treasury yields dip
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- Paradium AI (PAAI) Halted, News Pending
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance
October 29, 2025 7:08 AM EDTIonis Pharmaceuticals (NASDAQ: IONS) reported Q3 EPS of ($0.80), $0.42 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $157 million versus the consensus estimate of $130.76 million.
GUIDANCE:
Ionis Pharmaceuticals sees FY2025 EPS of $875.00-$900.00, versus the consensus of... More
